Rate-limiting Amino Acids in Endurance-trained Athlete

NCT ID: NCT02628249

Last Updated: 2019-04-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-09-30

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Protein requirements in individuals who participate in endurance-based exercise training have been suggested to be greater than the current recommended dietary allowance (RDA).

The biological value of protein depends on the amino acid composition. As liebig's law of the minimum, the protein synthesis is limited due to the lack of single rate limiting amino acid. In this case, the first rate limiting amino acid determines protein intakes to maximize the protein synthesis. Adding a small amount of rate-limiting amino acid to the diet improves the biological value of its protein diet.

The indicator amino acid oxidation (IAAO) method has clarified the individual amino acid requirement in children, normal healthy adult and clinical populations. however, the IAAO method has never been utilized for determining the first rate limiting amino acid.

Therefore, the purpose of this study is to address of IAAO method to be applied for determining the rate-limiting amino acid in endurance athlete.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Increased Metabolic Requirement Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Base protein

0.8 g/kg/d of protein provided as crystalline amino acid made after egg protein.

Group Type EXPERIMENTAL

Base protein

Intervention Type DIETARY_SUPPLEMENT

0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein

Sufficient protein

1.75 g/kg/d protein provided as crystalline amino acid made after egg protein.

Group Type EXPERIMENTAL

Sufficient protein

Intervention Type DIETARY_SUPPLEMENT

1.75 g/kg/d protein provided as crystalline amino acid modeled after egg protein.

Base + BCAA

Base protein intake + Branched chain amino acids

Group Type EXPERIMENTAL

Base protein

Intervention Type DIETARY_SUPPLEMENT

0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein

Branched chain amino acids

Intervention Type DIETARY_SUPPLEMENT

Branched chain amino acids modeled after egg protein.

Base + EAA

Base protein intake + essential amino acids.

Group Type EXPERIMENTAL

Base protein

Intervention Type DIETARY_SUPPLEMENT

0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein

Essential amino acids

Intervention Type DIETARY_SUPPLEMENT

Essential amino acids modeled after egg protein.

Base + NEAA

Base protein intake + non essential amino acids

Group Type EXPERIMENTAL

Base protein

Intervention Type DIETARY_SUPPLEMENT

0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein

Non essential amino acids

Intervention Type DIETARY_SUPPLEMENT

Non essential amino acids modeled after egg protein.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Base protein

0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein

Intervention Type DIETARY_SUPPLEMENT

Sufficient protein

1.75 g/kg/d protein provided as crystalline amino acid modeled after egg protein.

Intervention Type DIETARY_SUPPLEMENT

Branched chain amino acids

Branched chain amino acids modeled after egg protein.

Intervention Type DIETARY_SUPPLEMENT

Essential amino acids

Essential amino acids modeled after egg protein.

Intervention Type DIETARY_SUPPLEMENT

Non essential amino acids

Non essential amino acids modeled after egg protein.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Endurance-trained participants who regularly more than 40 km/week
* Ability to perform the exercise stimulus (20 km run) on metabolic trial.

Exclusion Criteria

* Inability to meet health and physical activity guidelines according to the physical activity readiness questionnaire (PAR-Q+)
* Inability to adhere to any of the protocol guidelines (i.e. alcohol, caffeine consumption)
* Regular tobacco use
* Illicit drug use
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Toronto

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Daniel Moore

Assistant professaor

Responsibility Role PRINCIPAL_INVESTIGATOR

References

Explore related publications, articles, or registry entries linked to this study.

Kato H, Suzuki K, Bannai M, Moore DR. Branched-Chain Amino Acids Are the Primary Limiting Amino Acids in the Diets of Endurance-Trained Men after a Bout of Prolonged Exercise. J Nutr. 2018 Jun 1;148(6):925-931. doi: 10.1093/jn/nxy048.

Reference Type DERIVED
PMID: 29746639 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IAAO-EA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.